On November 10, 2004, a study concerning the safety of Bextra (valdecoxib) linked the pain-relieving drug to an increase in heart attacks and strokes, along with other serious side effects. Bextra is Pfizer, Inc.'s newest cox-2 inhibitor prescribed to treat those suffering from osteoarthritis, rheumatoid arthritis, and menstrual cramping.

The release of the study comes after two other cox-2 inhibitor drugs have been found to also increase the risk of heart attack and strokes in users. ...MORE